Profitability problems continue at Molnlycke:
This article was originally published in Clinica
Sharp rises in fibre costs caused operating profits at Molnlycke to fall 21% to SKr 203 million ($27 million) in the first three months of 1995. Part of the Swedish pulp, paper and packaging group SCA, Molnlycke saw sales rise 25% to SKr 4,155 million during the same period. SCA's hygiene products division (of which Molnlycke is a part) recorded 12% growth for incontinence care products, while sales of clinical products increased 8%.
You may also be interested in...
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.